Description
Background:
Bermekimab (MABp1) is a human monoclonal antibody that targets interleukin-1alpa (IL-1). Bermekimab prevents tumour-related inflammation by neutralization of the biological activity of IL-1, including blocking the inflammatory induction of VEGFs and matrix metalloproteinases in order to inhibit neoangiogenesis and stromal remodeling in the tumor microenvironment.
Intended Use:
For Estimation of Bermekimab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Bermekimab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Bermekimab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Bermekimab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Bermekimab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!